glofitamab,Obinutuzumab 
roche
['lymsm', 'glofitamab', 'lymphoma']
at the #asco22 lymphoma session! i'll be live tweeting on this thread. first up: results from glofitamab phase ii trial. with fixed dose therapy, orr 52% with some durable responses in patients with cr. 12-month os 50%. #lymsm 
Hematology/oncology fellow. #lymsm & #mmsm outcomes researcher. Physician-publisher & founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????